摘要
观察恩替卡韦对失代偿期乙肝肝硬化患者的治疗效果和安全性。20例乙肝肝硬化失代偿期患者予恩替卡韦0.5mg,每天1次口服,持续治疗48周。观察治疗后12周、24周、48周病毒学、生化指标、凝血酶原活动度及Child-Pugh积分等变化情况。患者治疗前血清HBV DNA对数值平均为7.45±0.38 log拷贝/ml,在接受恩替卡韦治疗后12周、24周、48周时分别下降至4.71±0.44 log拷贝/ml(P<0.01)、3.74±0.56log拷贝/ml(P<0.01)、2.83±0.21 log拷贝/ml(P<0.01)(治疗后HBV DNA监测不到的数值为<5×102拷贝/ml)。与治疗前相比,在治疗48周时ALT、AST、TBIL、ALB、PTA及Child-Pugh积分等指标均有所改善(P<0.01)。恩替卡韦治疗失代偿期乙肝肝硬化患者在48周内既能有效抑制病毒复制,使HBV DNA水平下降,同时也可以改善肝功能、凝血酶原活动度及Child-Pugh积分等指标。
To evaluate the efficacy and safety of Entecavir in patients with hepatitis B virus（HBV） related decompensated cirrhosis.In this study,20 patients with HBV related decompensated cirrhosis received 0.5 mg of Entecavir once daily for 48 weeks.HBV DNA,ALT,AST,TBIL,PTA,and Child-Pugh score were quantified at baseline and at 12,24,48 weeks.The mean levels of serum HBV DNA was 7.45±0.38 log10 at baseline.At week 12,24 and 48 weeks,the mean levels of serum HBV DNA were 4.71±0.44 log10（P0.01）,3.74±0.56 log10（P0.01）,2.83±0.21 log10（P0.01）.（Undetectable serum HBV DNA level was 500 copies/ml）.At week 48 of treatment,levels of alanine amiotransferase（ALT）,aspartate transaminase（AST）,and total bilirubin（TBIL） and Child-Pugh score decreased significantly;levels of albubin（ALB） increased significantly.The 48-week Entecavir treatment resulted in virologic suppression.The Entecavir treatment could decrease the level of HBV DNA,improve liver function,inhibit HBV replication in patients with HBV related cirrhosis.In treatment of the patients with HBV related cirrhosis,Entecavir is potent to suppress HBV replication and delay progression of fibrosis.
出处
《医学与哲学（B）》
2011年第4期29-30,共2页
Medicine & Philosophy(B)
